FSHR and ovarian cancer: Positron emission tomography (PET) using an anti-FSHR monoclonal antibody (FSHR-mAb) conjugated with S-2-(4-isothiocyanatobenzyl)-1,4,7-triazacyclononane-1,4,7-triacetic acid (p-SCN-BnNOTA), and a radiotracer (64Cu) demonstrated a high affinity to FSHR in ovarian cancers compared to FSHR-negative tumors [36].